Last Posted: Feb 15, 2019
- Pharmacogenetic testing among patients with mood and anxiety disorders is associated with decreased utilization and cost: A propensity-score matched study.
Perlis Roy H et al. Depression and anxiety 2018 35(10) 946-952 - An economic model of the cost-utility of pre-emptive genetic testing to support pharmacotherapy in patients with major depression in primary care.
Sluiter Reinier L et al. The pharmacogenomics journal 2019 Jan - Does obtaining CYP2D6 and CYP2C19 pharmacogenetic testing predict antidepressant response or adverse drug reactions?
Solomon Haley V et al. Psychiatry research 2018 Dec 271604-613 - Pharmacogenetic guidelines and decision support tools for depression treatment: application to late-life.
Chang Donald D et al. Pharmacogenomics 2018 Nov 19(16) 1269-1284 - Cost-Effectiveness of a Pharmacogenetic Test to Guide Treatment for Major Depressive Disorder.
Groessl Erik J et al. Journal of managed care & specialty pharmacy 2018 Aug 24(8) 726-734 - FDA clears the first consumer genetic test for how well your medications may work — with caveats
R Robbins, StatNews, October 31, 2018 - Pharmacogenomics and Biomarkers of Depression.
Jha Manish K et al. Handbook of experimental pharmacology 2018 Oct - DNA Methylation as a Biomarker of Treatment Response Variability in Serious Mental Illnesses: A Systematic Review Focused on Bipolar Disorder, Schizophrenia, and Major Depressive Disorder.
Goud Alladi Charanraj et al. International journal of molecular sciences 2018 Oct 19(10) - In the race to use genetic tests to predict whether antidepressants will work, science might be getting left behind
R Robbins, StatNews, September 28, 2018 - Overview of pharmacogenomic testing in clinical practice.
Gross Tonya et al. The mental health clinician 2018 Sep 8(5) 235-241
No hay comentarios:
Publicar un comentario